Renal cell carcinoma

Common Name(s)

Renal cell carcinoma

Renal cell carcinoma (RCC) is one of the most common types of kidney cancers seen in adults. RCC occurs more often in men between the ages of 50 to 70. The kidneys help get rid of waste in the body. There are small tubes in the kidneys that help filter waste from the blood and help make urine. RCC occurs when cells start growing uncontrollably in the lining of these small tubes. Symptoms may not appear in the early stages of renal cell carcinoma, which is why renal cell carcinoma is normally advanced when found. Later symptoms may include blood in urine, a lump in the abdomen, weight loss, anemia, and loss of appetite. If untreated, it may spread to the lymph nodes, lungs, liver, adrenal glands, brain, or bones.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Renal cell carcinoma" returned 2544 free, full-text research articles on human participants. First 3 results:

Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
 

Author(s): Dana Livne-Segev, Maya Gottfried, Natalie Maimon, Avivit Peer, Avivit Neumann, Henry Hayat, Svetlana Kovel, Avishay Sella, Wilmosh Mermershtain, Keren Rouvinov, Ben Boursi, Rony Weitzen, Raanan Berger, Daniel Keizman

Journal: Isr. Med. Assoc. J.. 2014 Jun;16(6):347-51.

 

The VEGFR/PDGFR inhibitor sunitinib was approved in Israel in 2008 for the treatment of metastatic renal cell carcinoma (mRCC), based on an international trial. However, the efficacy of sunitinib treatment in Israeli mRCC patients has not been previously reported.

Last Updated: 25 Jul 2014

Go To URL
HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.
 

Author(s): Eva Juengel, Snigdha Nowaz, Jasmina Makarevi, Iyad Natsheh, Isabella Werner, Karen Nelson, Michael Reiter, Igor Tsaur, Jens Mani, Sebastian Harder, Georg Bartsch, Axel Haferkamp, Roman A Blaheta

Journal:

 

Targeted therapies have improved therapeutic options of treating renal cell carcinoma (RCC). However, drug response is temporary due to resistance development.

Last Updated: 28 Jun 2014

Go To URL
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.
 

Author(s): Jacob Farnebo, Per Grybäck, Ulrika Harmenberg, Anna Laurell, Peter Wersäll, Lennart K Blomqvist, Anders Ullén, Per Sandström

Journal:

 

To determine whether changes in the metabolism of metastatic renal cell carcinoma (mRCC) assessed by F18-FDG-PET after 14 and 28 days of treatment with tyrosine kinase inhibitors can predict overall and progression- free patient survival.

Last Updated: 21 Jun 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Renal cell carcinoma" returned 267 free, full-text review articles on human participants. First 3 results:

Tumor necrosis factor receptor 2: its contribution to acute cellular rejection and clear cell renal carcinoma.
 

Author(s): Jun Wang, Rafia S Al-Lamki

Journal: Biomed Res Int. 2013 ;2013():821310.

 

Tumor necrosis factor receptor 2 (TNFR2) is a type I transmembrane glycoprotein and one of the two receptors that orchestrate the complex biological functions of tumor necrosis factor (TNF, also designed TNF- α ). Accumulating experimental evidence suggests that TNFR2 plays an important ...

Last Updated: 18 Dec 2013

Go To URL
Renal mucinous tubular and spindle cell carcinoma: a report of 8 cases and review of the literature.
 

Author(s): Xiao-rong Wu, Yong-hui Chen, Jian-jun Sha, Ling Zhao, Ji-wei Huang, Juan-Jie Bo, Dong-ming Liu, Yi-ran Huang

Journal:

 

Mucinous tubular and spindle cell carcinoma of kidney (MTSCC-K) is a rare variant of renal tumor. The current data show most of MTSCCs are of low malignant potential and rare cases metastatic to lymph nodes have been reported; however, the recorded computed tomography (CT) and follow ...

Last Updated: 28 Feb 2014

Go To URL
Concurrent primary carcinoid tumor arising within mature teratoma and clear cell renal cell carcinoma in the horseshoe kidney: report of a rare case and review of the literature.
 

Author(s): Ke Sun, Qihan You, Ming Zhao, Hongtian Yao, Hua Xiang, Lijun Wang

Journal:

 

Primary carcinoid tumor arising in a mature teratoma of the horseshoe kidney is exceptionally rare and only 4 such cases have been reported in the world literature to date. The simultaneous occurrence of different subtypes of renal cell carcinoma (RCC) or RCC coexistence with non-RCC ...

Last Updated: 14 Nov 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Immunotherapy Study for Metastatic Renal Cell Cancer
 

Status: Not yet recruiting

Condition Summary: Metastatic Renal Cell Carcinoma; Metastatic Clear-cell Renal Cancer; Recurrent Renal Cell Carcinoma; Refractory Renal Cell Carcinoma; Metastatic Kidney Cancer

 

Last Updated: 28 Aug 2014

Go to URL
AMG 172 First in Human Study in Patients With Kidney Cancer
 

Status: Recruiting

Condition Summary: Renal Cell Adenocarcinoma; Clear Cell Renal Carcinoma; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma

 

Last Updated: 17 Oct 2014

Go to URL
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
 

Status: Recruiting

Condition Summary: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma

 

Last Updated: 18 Dec 2014

Go to URL